Anaplastic Thyroid Cancer – Pipeline Review, 2019

Anaplastic Thyroid Cancer is also referred to as undifferentiated thyroid cancer and found to be more prominently occurring in geriatric patients. Anaplastic thyroid cancer is very rare compared to other types of thyroid cancers and makes up only 2% of all types of thyroid cancer. At present, the actual cause of anaplastic thyroid cancer is unknown however, it is found that differentiated thyroid cancer might lead to anaplastic thyroid cancer. This type of cancer is found to be lethal and considered as one of the most destructive cancers. The five-year survival rate of anaplastic thyroid cancer is less than 5% and it has been observed that most patients die within 2 to 3 months of diagnosis.

 At present, treatment for anaplastic thyroid cancer is mainly palliative. Current treatment of anaplastic thyroid cancer includes complete surgical removal of cancerous cells. The treatment depends upon the stage of cancer and patients overall health.

Many research institutes have focussed on studying and developing new methods for the treatment of anaplastic thyroid cancer. For instance; lenvatinib, which is being studied by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan, is currently in phase-2 clinical trials for the study on assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer.  

To know how our report can help streamline your business, Speak to Analyst

At present more than 60% of the pipeline candidates for anaplastic thyroid cancer are in the phase 2 stage and the majority of the studies have been sponsored by research institutes.

 Report Description

 The report on ‘Anaplastic Thyroid Cancer – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Anaplastic Thyroid Cancer. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Anaplastic Thyroid Cancer.

 The report on ‘Anaplastic Thyroid Cancer – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

 Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; the route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

 Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Anaplastic Thyroid Cancer
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Anaplastic Thyroid Cancer
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary